Tirzepatide-based evidence from the SURPASS (Researching Tirzepatide in Patients with Type 2 Diabetes for Glycemic Control and Weight Management) trials (SURPASS-1 NCT03954834 and SURPASS-5 NCT04039503) demonstrated dose-dependent, significant weight loss over 40 weeks compared with placebo, along with reductions in BMI and waist circumference [62, 63]
Solvent Injection Methods: These methods are used for encapsulating hydrophobic drugs
Cofactors can be classed as prosthetic groups or coenzymes depending on how tightly they are bound to the enzyme
Further translational research and prospective clinical trials are required to clarify causality, determine effect size, and identify high-risk groups most likely to benefit
Our care is centered around you, offering treatments that fit your wellness goals
Yu WQ, Zhang SY, Fu SQ, Fu QH, Lu WN, Zhang J, Liang ZY, Zhang Y, Liang TB